TY  - JOUR
AU  - Kahan, Zsuzsanna
AU  - Gil-Gil, Miguel
AU  - Ruiz-Borrego, Manuel
AU  - Carrasco, Eva
AU  - Ciruelos, Eva
AU  - Muñoz, Montserrat
AU  - Bermejo, Begoña
AU  - Margeli, Mireia
AU  - Anton, Antonio
AU  - Casas, Maribel
AU  - Csoszi, Tibor
AU  - Murillo, Laura
AU  - Morales, Serafin
AU  - Calvo, Lourdes
AU  - Lang, Istvan
AU  - Alba, Emilio
AU  - de-la-Haba-Rodriguez, Juan
AU  - Ramos, Manuel
AU  - Alvarez-Lopez, Isabel 
AU  - Gal-Yam, Einav
AU  - Garcia-Palomo, Andres
AU  - Alvarez, Elena
AU  - Gonzalez-Santiago, Santiago
AU  - Rodriguez, Cesar A
AU  - Servitja, Sonia
AU  - Corsaro, Massimo
AU  - Rodrigalvarez, Graciela
AU  - Zielinski, Christoph
AU  - Martin, Miguel
PY  - 2021
DO  - 10.1016/j.ejca.2021.07.004
UR  - http://hdl.handle.net/10668/18401
T2  - European journal of cancer (Oxford, England : 1990)
AB  - The PEARL study showed that palbociclib plus endocrine therapy (palbociclib/ET) was not superior to capecitabine in improving progression-free survival in postmenopausal patients with metastatic breast cancer resistant to aromatase inhibitors, but was...
LA  - en
PB  - Elsevier
KW  - CDK4/6 inhibitor
KW  - Endocrine therapy
KW  - Health-related quality of life
KW  - Hormone receptor–positive metastatic breast cancer
KW  - Palbociclib
KW  - Androstadienes
KW  - Antimetabolites, antineoplastic
KW  - Antineoplastic agents, hormonal
KW  - Antineoplastic combined chemotherapy protocols
KW  - Aromatase inhibitors
KW  - Breast neoplasms
KW  - Capecitabine
KW  - Disease progression
KW  - Estrogen receptor antagonists
KW  - Europe
KW  - Female
KW  - Fulvestrant
KW  - Health status
KW  - Humans
KW  - Israel
KW  - Neoplasm metastasis
KW  - Patient reported outcome measures
KW  - Piperazines
KW  - Postmenopause
KW  - Progression-free survival
KW  - Protein kinase inhibitors
KW  - Pyridines
KW  - Quality of life
KW  - Time factors
TI  - Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study.
TY  - research article
VL  - 156
ER  -